Core Insights - Tilray Brands, Inc. (TLRY) is set to report its third-quarter fiscal 2026 results on April 1, 2026, with expected revenues of $205.9 million, reflecting a 10.9% increase year-over-year, and a narrower loss of 14 cents per share compared to a loss of $1 in the same quarter last year [1][9] Group 1: Financial Performance - The Zacks Consensus Estimate indicates a revenue increase to $205.9 million, up 10.9% from the previous year [1][9] - The expected quarterly loss is 14 cents per share, which is an improvement from the $1 loss reported in the year-ago quarter [1][9] - In the last reported quarter, the company experienced a negative earnings surprise of 192.9%, with an average negative surprise of 19.1% over the last four quarters [2] Group 2: Business Strategy and Focus - Tilray Brands is focused on creating a diversified global consumer packaged goods platform, emphasizing cannabis, beverages, and wellness, with a particular focus on higher-margin opportunities in international markets like Europe [3][4] - The company aims to strengthen its position in the medical cannabis sector through research and clinical trials, alongside a broad product portfolio [3][4] - The strategy includes expanding access, fostering innovation, and supporting regulatory progress globally, which is expected to positively impact performance [4] Group 3: Challenges and Market Conditions - Despite the positive outlook, Tilray Brands faces underlying weaknesses, including margin pressures due to a higher mix of lower-margin cannabis products and ongoing challenges in the beverage segment [5][9] - The beverage business is projected to generate revenues of $47.6 million, down 15% from the previous year, reflecting ongoing SKU rationalization and headwinds in the craft beer segment [5][6] - Management is optimistic about the beverage category's potential, focusing on product diversification and operational improvements [6]

Core Insights - The Canadian cannabis sector is evolving with a focus on U.S. market entry and federal reform discussions in the U.S. acting as a catalyst for growth [1][2] - Companies are diversifying into beverages, wellness, and international markets to offset slower growth in Canada, making strong balance sheets and revenue growth increasingly important [2] Company Summaries Tilray Brands Inc. - Tilray is one of the most diversified cannabis companies globally, with a strong presence in Canada and Europe, and has expanded into the U.S. through beverages and wellness products [2][3] - The company operates in over 20 countries with more than 40 brands, primarily gaining U.S. exposure through craft beer and distribution businesses, positioning itself well for potential federal legalization [3][4] - For fiscal 2026, Tilray reported approximately $217 million in quarterly revenue, reflecting modest year-over-year growth, with international cannabis sales increasing and gross profit reaching roughly $57 million [5][6] Canopy Growth Corporation - Canopy Growth is a well-recognized cannabis company with a strong presence in Canada's recreational market and is restructuring operations to improve profitability [7][8] - The company is strategically positioned for U.S. expansion through partnerships with U.S. cannabis operators, although full participation is contingent on federal legalization [8][10] - Canopy has achieved significant cost savings through restructuring, reported a strong cash position, and is moving closer to positive adjusted EBITDA, indicating improving financial health [11][12] Village Farms International, Inc. - Village Farms transitioned from a greenhouse produce grower to cannabis through its Pure Sunfarms brand, focusing on producing low-cost, high-quality products in Canada's retail cannabis market [13][15] - The company has exposure to the U.S. market through hemp-derived CBD operations and is expanding internationally, building a diversified revenue base [15][16] - Financially, Village Farms has shown steady improvement, focusing on increasing margins and controlling expenses, which has strengthened its cannabis segment performance [16][17] Market Outlook - Canadian cannabis stocks are considered speculative but hold potential, largely dependent on U.S. federal reform [17][18] - Tilray stands out for its global diversification and improved financials, Canopy Growth offers a turnaround story with strong liquidity, and Village Farms presents a disciplined, cost-efficient business model [18]

The company introduced Shock Top’s first-ever high-ABV offering, High Voltage, as part of its broader push to expand and innovate within the beverage segment. The product is a double wheat beer with a 9.6% ABV, featuring bold orange flavors and real orange peel.This new product is expected to roll out in stores nationwide starting at $2.99, reflecting the brand’s commitment to meeting consumer demand for high-ABV options.The launch will begin in Southern California before expanding further, showcasing Shock ...

A Double Wheat Brew that Surges with Big, Shocking Citrus, Shock Top High Voltage is Boldly Strong at 9.6% ABV PORTLAND, Ore., March 31, 2026 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Beverages, known for its bold flavors and unfiltered wheat ales, today announced its first-ever high-ABV double wheat beer, an electric new twist on what a wheat can be. High Voltage delivers a shockwave of juicy orange flavor amped by bright citrus zest and a bold wheat backbone. Prepare to be jolte ...

Core Viewpoint - Tilray Brands, Inc. has partnered with The Magnum Ice Cream Company to launch a new line of ready-to-drink alcoholic beverages inspired by iconic Popsicle flavors, targeting adult consumers in the U.S. market [3][4]. Company Overview - Tilray Brands, Inc. is a leading global lifestyle and consumer packaged goods company, listed on Nasdaq and TSX [3]. - The Magnum Ice Cream Company is the world's largest ice cream company, generating €7.9 billion in revenue in 2025, with a presence in 80 markets [6][7]. Product Launch - The new Popsicle® Hard flavored beverages will feature a 5% ABV and include flavors such as Hard Cherry, Hard Orange, and Hard Grape, available in a variety pack [4]. - The Popsicle Hard Variety Pack will be available in select retailers nationwide starting March 2026, with a special Popsicle Hard Firecracker beverage launching in May 2026 [4][5]. Strategic Goals - The partnership aims to leverage Tilray's beverage innovation expertise and Popsicle's nostalgic brand appeal to create a unique adult refreshment experience [5]. - The initiative reflects Tilray's strategy to build a dynamic portfolio of brands that resonate with consumers across various occasions [5].

Core Viewpoint - Tilray Brands, Inc. is set to release its financial results for the third fiscal quarter ending February 28, 2026, on April 1, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be announced before the financial markets open on April 1, 2026 [1] - A live conference call and audio webcast will be held at 8:30 AM Eastern Time on the same day to discuss the results [2] Group 2: Company Overview - Tilray is a leading global lifestyle and consumer packaged goods company with operations in multiple regions including Canada, the United States, Europe, Australia, and Latin America [3] - The company focuses on the cannabis, beverage, wellness, and entertainment sectors, aiming to elevate lives through moments of connection [3] - Tilray supports over 40 brands in more than 20 countries, offering a range of products including cannabis offerings, hemp-based foods, and craft beverages [3]

Core Insights - Irwin Simon, CEO of Tilray Brands, is expanding the company's beer offerings by acquiring UK-based BrewDog for $53 million, significantly lower than its peak valuation of $2 billion [1][4] - The acquisition is part of Simon's strategy to revitalize declining brands, leveraging his experience from his time at Hain Celestial Group [2] Company Strategy - Tilray was already the fourth-largest craft brewer in the US by sales volume before the BrewDog acquisition [3] - The company plans to market BrewDog's products to millennials and Gen Z through pop-up events at various locations, including East Hampton's Maidstone Hotel and Lobster Roll's Hamptons locations [3][5] - Simon aims to sell Tilray's craft beers, including Montauk Brewing Co. beverages, at BrewDog pubs in both the US and Europe [5][8] Market Positioning - BrewDog, known for its rebellious image, faced challenges due to overexpansion, which included opening multiple locations across several countries [2][9] - Simon is optimistic about the brand's potential in the UK and the US, despite rising anti-US sentiment in Europe [8]

Core Viewpoint - James Watt has expressed disappointment over Tilray Brands' decision to exclude early investors, known as "equity punks," from the recent acquisition of BrewDog, which he founded in 2007 [2][5]. Group 1: Acquisition Details - Tilray Brands acquired BrewDog's brand, brewery, and 11 pubs for £33 million, a significant drop from BrewDog's previous valuation of £1 billion [4][8]. - TSG Consumer Partners, which invested in BrewDog in 2017, did not participate in the sale and left empty-handed, along with James Watt and co-founder Martin Dickie [4]. Group 2: Investor Impact - The acquisition resulted in the complete loss of investments for BrewDog's equity punks, which Watt criticized as unacceptable [5][6]. - Watt had previously positioned himself as a protector of these smaller investors, indicating that he would ensure they retained equity if he had acquired the business [4][5]. Group 3: Management and Future Direction - Irwin Simon, Tilray's CEO, has indicated a desire to move past Watt's involvement and the associated controversies, including claims of a toxic workplace culture [7]. - Simon stated that by the time he took over, there was "no money left," highlighting the financial challenges faced by BrewDog [9].

Core Viewpoint - Tilray is expanding its product offerings in Australia, focusing on enhancing treatment options for healthcare professionals and patients, which reflects its commitment to this key growth market [1][5]. Product Expansion - The expansion includes new products under the Redecan and Good Supply brands, offering medical cannabis flower, extracts, vapes, and pastilles to improve access to high-potency, patient-focused solutions [1][5]. Market Performance - Despite a broader market decline, Tilray's stock movement is more influenced by general market trends rather than company-specific issues, with the Materials sector down 2.18% [2]. - Tilray's stock is currently trading 11.3% below its 20-day simple moving average (SMA) and 30% below its 100-day SMA, indicating a bearish trend in the short- to medium-term [3]. Technical Analysis - The Relative Strength Index (RSI) is at 32.93, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is at -0.3179, suggesting bearish pressure on the stock [4]. - Key resistance level for the stock is identified at $7.00 [4]. Earnings and Analyst Outlook - The next financial update for Tilray Brands, Inc. is estimated to be on April 7, 2026 [6]. - The stock currently carries a Hold Rating, with Roth Capital recently lowering its target price to $10.00 [7]. ETF Exposure - Tilray has a significant weight of 15.49% in the Amplify Alternative Harvest ETF (NYSE:MJ), indicating that any significant inflows or outflows for this ETF will likely impact Tilray's stock price [8]. Price Action - As of the latest publication, Tilray's stock price was down 2.01% at $6.59, with an estimated loss of 1 cent per share and a revenue estimate of $203.15 million, up from $185.78 million [9].

Core Viewpoint - Tilray's stock price has significantly declined, losing crucial support, raising concerns about a potential drop to $5 as demand for cannabis companies decreases [1][6]. Group 1: Stock Performance - Tilray's stock (TLRY) fell to $6.7, marking its lowest level since August of the previous year, and has dropped 72% from its peak last year [1]. - The stock has decreased from $23.23 to $6.73, reflecting a broader trend in the cannabis sector, with the AdvisorShares Pure US Cannabis ETF (MSOS) also declining from $7.25 to $3.78 [2][6]. Group 2: Market Catalysts - The decline in Tilray's stock is attributed to waning hype surrounding the potential reclassification of cannabis in the U.S., with the Trump administration not addressing the issue since last year [2][3]. - The anticipated reclassification could significantly impact the cannabis industry by allowing easier expansion into the U.S. market, which Tilray currently does not serve [3]. Group 3: Financial Performance - Despite the stock decline, Tilray's net revenue increased by 3% to $217 million in the second quarter, with the cannabis segment also seeing a 3% rise to $67.5 million [4]. - Distribution revenue, including Tilray Pharma, rose to $85.3 million from $67.5 million year-over-year [5]. - The company's gross profit grew from $8.4 million to $11 million, and net losses narrowed from $85.3 million to $43.5 million [7]. Group 4: Future Projections - Analysts predict continued revenue growth for Tilray, estimating an 8.38% increase to $201 million, with annual revenue projected to rise by 5.2% to over $864 million in the current fiscal year, and reaching $1.1 billion next year [8]. Group 5: Technical Analysis - The stock has fallen below the critical support level of $6.97, indicating a potential further decline, with the next target being the $5 support level, representing a 25% drop from the current price [9][10].